Merck KGaA is conducting a global Phase 3 trial of Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy.
Preliminary results of Oncothyreon's ongoing Phase 1 trial of PX-866, an inhibitor of PI-3 kinase, were presented by Dr. Antonio Jimenez,
"We are excited to have seen stabilization of disease in previously progressing patients, as well as clearcut inhibition of PI-3 kinase activity, even in the early cohorts in this dose escalation trial," said Dr. Kirkman. "We believe these findings may reflect the fact that PX-866 is an irreversible inhibitor of PI-3 kinase, which distinguishes it from other PI-3 kinase inhibitors currently in clinical development."
|SOURCE Oncothyreon Inc.|
Copyright©2009 PR Newswire.
All rights reserved